Neochem Bio Solutions Ltd

AI
Neochem Bio Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Neochem Bio Solutions Ltd

₹ 106 1.05%
05 Nov - close price
neochem.in NSE - SME: NEOCHEM
About

Incorporated in 2006, Neochem Bio Solutions Ltd. is engaged in the business of manufacturing of specialty performance chemicals.[1]

Key Points

Business Profile:[1]
Operates as a specialty performance chemical company with 350+ customized formulations across four primary product segments, ''Polymers, Surfactants, Silicones
and esters /bio-based sustainable solutions''.
It has 50+ pan‑India authorized distributors, serving
225+ domestic customers, with customer presence
in 12 countries, 22,000 MTPA ISO‑certified capacity
in Ahmedabad, 40 registered trademarks, an in‑house
R&D lab, and a Zero Liquid Discharge facility.[2]

Website NSE - SM
  • Market Cap ₹ 182 Cr.
  • Current Price ₹ 106
  • High / Low ₹ 121 / 63.0
  • Stock P/E 23.6
  • Book Value ₹
  • Dividend Yield 0.00 %
  • ROCE 27.2 %
  • ROE 48.4 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 31.0%

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals

Part of Nifty SME Emerge

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sales
Operating Profit
OPM %
Interest
Depreciation
Profit before tax
Tax %
EPS in Rs
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025
48.19 61.15 84.17
43.95 55.16 71.05
Operating Profit 4.24 5.99 13.12
OPM % 8.80% 9.80% 15.59%
0.60 0.86 1.98
Interest 2.10 2.96 3.51
Depreciation 1.22 1.22 1.33
Profit before tax 1.52 2.67 10.26
Tax % 28.95% 32.58% 24.46%
1.07 1.80 7.75
EPS in Rs 1.13 1.54 6.62
Dividend Payout % 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 38%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 330%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 31%
Last Year: 48%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025
Equity Capital 5.43 6.68 6.68
Reserves 2.63 5.33 13.08
26.24 33.32 35.63
16.31 18.73 23.50
Total Liabilities 50.61 64.06 78.89
14.67 18.81 18.67
CWIP 0.04 0.03 0.06
Investments 0.00 0.00 0.00
35.90 45.22 60.16
Total Assets 50.61 64.06 78.89

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025
-0.74 1.96 2.59
-3.35 -7.86 -1.69
3.76 6.20 -1.20
Net Cash Flow -0.34 0.30 -0.30
Free Cash Flow -4.07 -3.37 1.45
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit -11% 40% 26%

Ratios

Consolidated / View Standalone

Mar 2023 Mar 2024 Mar 2025
Debtor Days 109.22 102.90 109.63
Inventory Days 174.77 172.24 157.02
Days Payable 156.98 133.36 107.72
Cash Conversion Cycle 127.01 141.78 158.93
Working Capital Days 20.53 32.29 39.33
ROCE % 14.09% 27.20%

Insights

In beta
Mar 2023 Mar 2024 Mar 2025 Mar 2026
Capacity Utilization
% ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Domestic Customer Count
count ・Standalone data
Esters & Bio-based Segment Revenue Share
% ・Standalone data
Home & Personal Care (HPC) Industry Revenue Share
% ・Standalone data
Production Volume
MT ・Standalone data
Textile Industry Revenue Share
% ・Standalone data
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

2 Recently
Dec 2025Mar 2026Sep 2026
66.70% 66.72% 66.88%
1.99% 0.18% 0.18%
13.19% 15.82% 12.46%
18.12% 17.28% 20.47%
No. of Shareholders 861406525

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls